# Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

> **NCT02744833** · PHASE1,PHASE2 · TERMINATED · sponsor: **GlycoMimetics Incorporated** · enrollment: 2 (actual)

## Conditions studied

- Deep Venous Thrombosis

## Interventions

- **DRUG:** GMI-1271
- **DRUG:** Enoxaparin Sodium (Lovenox®)

## Key facts

- **NCT ID:** NCT02744833
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The trial was funded in part by a grant; the trial closed when the grant ended.
- **Last updated:** 2019-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02744833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02744833, "Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02744833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*